blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3732204

EP3732204 - ANTI-RENALASE ANTIBODIES FOR THE TREATMENT AND PREVENTION OF DISEASES AND DISORDERS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  03.11.2023
Database last updated on 29.10.2024
FormerRequest for examination was made
Status updated on  02.10.2020
FormerThe international publication has been made
Status updated on  06.07.2019
Most recent event   Tooltip06.05.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Yale University
Two Whitney Avenue
New Haven CT 06510 / US
[2020/45]
Inventor(s)01 / DESIR, Gary
11 Zak Hill Drive
Woodbridge, CT 06525 / US
02 / NELSON, Bryce
23 Anderson Avenue
West Haven, CT 06516 / US
 [2020/45]
Representative(s)Leonard, Thomas Charles, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2020/45]
Application number, filing date18897086.727.12.2018
[2020/45]
WO2018US67611
Priority number, dateUS201762611609P29.12.2017         Original published format: US 201762611609 P
[2020/45]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019133667
Date:04.07.2019
Language:EN
[2019/27]
Type: A1 Application with search report 
No.:EP3732204
Date:04.11.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 04.07.2019 takes the place of the publication of the European patent application.
[2020/45]
Search report(s)International search report - published on:US04.07.2019
(Supplementary) European search report - dispatched on:EP20.12.2021
ClassificationIPC:C07K16/40, C07K16/30, C07K16/18, A61P35/00, A61K39/00, G01N33/574
[2021/42]
CPC:
C07K16/40 (EP,CN,US); A61K47/6801 (CN); A61K47/6865 (CN);
A61K47/6871 (CN); A61P1/16 (CN); A61P1/18 (CN);
A61P13/12 (CN); A61P35/00 (EP,CN); A61P9/00 (CN);
C07K16/30 (EP); C07K16/3053 (CN); G01N33/5743 (EP,US);
G01N33/57438 (EP); A61K2039/505 (EP,CN); C07K2317/24 (EP,US);
C07K2317/33 (EP); C07K2317/34 (EP); C07K2317/55 (EP);
C07K2317/56 (CN); C07K2317/565 (EP,CN,US); C07K2317/73 (EP);
C07K2317/92 (EP,CN,US); G01N2800/067 (EP); G01N2800/08 (EP);
G01N2800/24 (EP); G01N2800/32 (EP); G01N2800/347 (EP) (-)
Former IPC [2020/45]C07K16/40, C07K16/30, C07K16/18
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/45]
TitleGerman:ANTI-RENALASE-ANTIKÖRPER ZUR BEHANDLUNG UND VORBEUGUNG VON KRANKHEITEN UND STÖRUNGEN[2020/45]
English:ANTI-RENALASE ANTIBODIES FOR THE TREATMENT AND PREVENTION OF DISEASES AND DISORDERS[2020/45]
French:ANTICORPS ANTI-RÉNALASE POUR LE TRAITEMENT ET LA PRÉVENTION DE MALADIES ET DE TROUBLES[2020/45]
Entry into regional phase03.07.2020National basic fee paid 
03.07.2020Search fee paid 
03.07.2020Designation fee(s) paid 
03.07.2020Examination fee paid 
Examination procedure03.07.2020Examination requested  [2020/45]
22.07.2022Amendment by applicant (claims and/or description)
03.11.2023Despatch of a communication from the examining division (Time limit: M06)
03.05.2024Reply to a communication from the examining division
Fees paidRenewal fee
28.12.2020Renewal fee patent year 03
27.12.2021Renewal fee patent year 04
27.12.2022Renewal fee patent year 05
27.12.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]WO2015200790  (UNIV YALE [US]);
International search[X]US2017226228  (DESIR GARY [US], et al);
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.